AU5785998A - New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof - Google Patents

New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof

Info

Publication number
AU5785998A
AU5785998A AU57859/98A AU5785998A AU5785998A AU 5785998 A AU5785998 A AU 5785998A AU 57859/98 A AU57859/98 A AU 57859/98A AU 5785998 A AU5785998 A AU 5785998A AU 5785998 A AU5785998 A AU 5785998A
Authority
AU
Australia
Prior art keywords
composition according
bulk density
formulation
budesonide
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU57859/98A
Other versions
AU731192B2 (en
Inventor
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU5785998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra AB filed Critical Astra AB
Publication of AU5785998A publication Critical patent/AU5785998A/en
Application granted granted Critical
Publication of AU731192B2 publication Critical patent/AU731192B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

NEW FORMULATION FOR INHALAΗON HAVING A POURED BULK DENSITY OF 0.28 TO 0.38 G/ML, A PROCESS FOR PREPARING THE FORMULATION AND THE USE THEREOF
Field of the Invention
The present invention provides a new pharmaceutical formulation, its preparation and its use.
Background to the Invention
Potent drugs for administration by inhalation are generally formulated in association with carriers such as lactose because of the problem of preparing accurate doses. When such drugs are diluted, variations in the weight of the formulation result in a smaller drug dosage variation rate compared with when they are not diluted. These formulations have generally consisted of coarse particles of the carrier with fine particles of the drug, which combination is generally known as an ordered mixture.
The invention provides an improved formulation which, in systems designed to imitate inhalation has been found to give an improved dispersion of the drug.
Description of the Invention
According to the invention there is provided a dry powder composition comprising one or more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml, preferably from 0.30 to 0.36 g/ml.
The poured bulk density according to the present invention is measured using known techniques, for example those described in "Powder testing guide: Methods of measuring the physical properties of Bulk powders" L. Svarovsky, Elsevier Applied Science 1987, pp 84-86. A potent pharmaceutically active substance suitable for use in the invention is, for example, an antiarrhythmic drug, tranquiliser, cardiac glycoside, hormone, hypertensive drug, antidiabetic or anticancer drug, sedative or analgesic drug, antibiotic, antirheumatic drug, immunotherapy, antifungal or antihypotension drug, vaccine, antiviral drug, protein (e.g. insulin), peptide, vitamin, or a cell surface receptor blocker. It is preferably a glucocorticosteroid, particularly one which is metabolised rapidly, for example beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, budesonide, rofleponide or derivatives thereof, momethasone, tipredane, RPR 106541 and/or a β2-agonist such as terbutaline, salbutamol, formoterol, salmeterol, TA 2005, pircumarol or a pharmaceutically acceptable salt thereof; and/or a prophylactic agent such as sodium chromoglycate or nedocromil sodium.
Suitable physiologically acceptable salts include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4- chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate or oleate salts or solvates thereof.
The carrier substance is preferably a mono-, di- or polysaccharide, a sugar alcohol or another polyol. Suitable carriers are, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch. Lactose is particularly preferred, especially in the form of its monohydrate.
The ingredients of the formulation according to the invention must both be in a finely divided form, i.e. their mass median diameter should generally be less than 10 μm, preferably from 1 to 7 μm, as measured by a laser diffraction instrument or a coulter counter. The ingredients may be produced in the desired particle size using methods known to those of skill in the art, e.g. milling, micronisation or direct precipitation. The combination of budesonide and formoterol is particularly preferred. Formoterol is preferably used in the form of its fumarate, especially the dihydrate.
When the one or more potent pharmaceutically active substances used in the invention are formoterol and budesonide, the molar ratio of formoterol to budesonide in the composition of the invention is preferably from 1 :2500 to 12:1, more preferably from 1 :555 to 2:1, most preferably from 1 :133 to 1:6. The composition according to the invention is preferably formulated to provide a daily dose of formoterol of from 2 to 120 nmol (more preferably from 7 to 70 nmol). When formoterol is used in the form of formoterol fumarate dihydrate, the composition is preferably formulated to provide a daily dose of formoterol fumarate dihydrate of from 1 to 50 μg, more preferably from 3 to 30 μg. The composition according to the invention is preferably formulated to provide a daily dose of budesonide of from 45 to 2200 μg, more preferably from 65 to 1700 μg.
More preferably the composition of the invention comprises, as a unit dose, 6μg of formoterol fumarate dihydrate and lOOμg of budesonide, or 4.5μg of formoterol fumarate dihydrate and 80μg of budesonide, either of which can be administered up to four times a day. Alternatively the composition of the invention comprises, as a unit dose, 12μg of formoterol fumarate dihydrate and 200μg of budesonide, or 9μg of formoterol fumarate dihydrate and 160μg of budesonide, either of which is administered once or twice a day.
Most preferably the composition used in the invention comprises, as a unit dose, 6μg of formoterol fumarate dihydrate and 200μg of budesonide, or 4.5μg of formoterol fumarate dihydrate and 160μg of budesonide, either of which is administered up to four times a day. Alternatively the composition of the invention comprises, as a unit dose, 12μg of formoterol fumarate dihydrate and 400μg of budesonide, or 9μg of formoterol fumarate dihydrate and 320μg of budesonide, either of which is administered once or twice a day. According to the invention there is further provided a process for preparing a composition according to the invention which comprises
(a) micronising the one or more potent pharmaceutically active substances and the carrier substance; (b) optionally conditioning the product; and
(c) spheronizing until the desired bulk density is obtained. The process preferably further comprises a low energy remicronisation step after step (b).
The formulation according to the invention may be made by conventional techniques known er se. Such production processes generally comprise micronising the ingredients to the required size, removing any amorphous areas on the particles obtained by, for example, the methods described in WO 92/18110 or WO 95/05805 and then agglomerating, spheronising and sieving the powder obtained. The size of the agglomerates obtained is preferably in the range of from 100 to 2000 μm, more preferably from 100 to 800 μm. The bulk density of the formulation produced may be adjusted by varying the components and the process empirically, for example the bulk density can be increased by lengthening the time in which the particles are tumbled in a spheronising device.
In solid-solid mixing, one of the most important features is to ensure content uniformity. The major problem encountered in the powder mixing of fine powders is the inability of mixers to break down powder agglomerates. It has been found that a remicronisation step after the conditioning step of the fine powder with low energy input is advantageous. It should generally be carried out using enough energy to break down powder agglomerates but not with so much energy that the size of the particles themselves is affected. Such a step gives a composition wherein the active substance and carrier substance are substantially uniformly distributed, having for example a relative standard deviation of less than 3% (preferably less than 1%) and does not disturb the crystallinity of the fine particles. The formulation according to the invention may be administered using any known dry powder inhaler, for example the inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler, for example Turbuhaler (trade mark). The invention further provides use of a composition according to the invention in the manufacture of a medicament for use in therapy. The composition according to the invention is useful in the treatment of respiratory disorders, particularly asthma. The invention also provides a method of treating a patient suffering from a respiratory disorder which comprises administering to the patient a therapeutically effective amount of a composition according to the invention.
The invention is illustrated, but not limited, by reference to the following Examples.
Example 1
0.0315 Parts of formoterol fumarate dihydrate and 2.969 parts of lactose monohydrate are mixed in a tumbling mixer (Turbula) to an evenly distributed mixture, whereafter the mixture is micronised in a spiral jet mill using a pressure and feeding rate suitable to obtain a particle size of less than 3 μm (mass median diameter as measured by a coulter counter). The micronised particles were then treated using the method disclosed in WO 95/05805 to remove amorphous regions in their crystal structure. The powder was then agglomerated by feeding the powder into a twin screw feeder (K-Tron), sieving in an oscillating sieve (0.5 mm mesh size), spheronising in a rotating pan with a peripheral speed of 0.5m/s for 4 minutes and then sieving again using the same sieve, then spheronising once more for 6 minutes before final sieving (mesh size 1.0 mm) giving a powder with a bulk density of 0.32g/ml.
Example 2
Example 1 was repeated but the powder was remicronised in a spiral jet mill at a lower pressure (about 1 bar) after micronisation and conditioning such that the step of treating the particles in the manner described in WO 95/05805 was not required giving a powder with a bulk density of 0.32 g/ml.
Example 3 9 Parts of budesonide and 91 parts of lactose monohydrate were micronised separately in a spiral jet mill at a pressure of about 6-7 bars to give a particle size of less than 3 μm before being mixed thoroughly in a Turbula mixer. Before mixing, the lactose monohydrate powder was conditioned according to the method described in WO 95/05805. The mixture was remicronised in a spiral jet mill at a pressure of only about 1 bar to obtain a uniform mixture. The powder was then agglomerated and spheronised as described in Example 1 to obtain a bulk density of 0.35 g/ml.
Example 4
60 Parts of terbutaline sulphate were micronized to a mass medium diameter of less than 2 μm in a Alpin mill lOOAFG and thereafter conditioned according to the method described in US 5562923. 40 Parts of lactose monohydrate were micronized (Alpin mill lOOAFG) down to a mass medium diameter of less than 3 μm and thereafter conditioned according to the method described in WO 95/05805. The micronized and conditioned terbutaline sulphate and lactose monohydrate were mixed thoroughly in a Turbula mixer. The mixture was remicronised in a spiral jet mill at a pressure of only about 1 bar to obtain an evenly distributed mixture. The powder was then agglomerated and spheronised as described in Example 1 to obtain a bulk density of 0.28 g/ml.
Example 5
Example 4 was repeated with 30 parts of terbutaline sulphate and 70 parts of lactose monohydrate to give a powder with a bulk density of 0.31 g/ml. Example 6
5.2 Parts of formoterol fumarate dihydrate and 896.8 parts of lactose monohydrate were mixed in a tumbling mixer to an evenly distributed mixture, whereafter the mixture was micronised in a spiral mill using a pressure and feeding rate suitable to obtain a particle size of less than 3 μm (mass medium diameter as measured by a coulter counter). The micronised particles were then treated using the method described in WO 95/05805 to remove amorphous regions in their crystal structure. 98 parts of micronised budesonide were added and the mixture was remicronized at a lower pressure in a spiral jet mill to a homogenous mixture. The powder was then agglomerated by feeding into a screw feeder (K-Tron), sieved in an ocillating sieve (0.5 mm mesh size), spheronised in a rotating pan with a speed of 23 rpm for 10 minutes, then sieved again (0.5 mm mesh size), spheronised once more before final sieved (0.8 mm mesh size) to give a powder with a bulk density of 0.34 g/ml.
Example 7
Example 6 was repeated with identical conditions but using 5.2 parts of micronized formoterol fumarate dihydrate, 798.8 parts of micronized lactose monohydrate and 196 parts of micronized budesonide. The bulk density obtained was 0.34 g ml.

Claims (9)

Claims
1. A dry powder composition comprising one or more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml.
2. A composition according to claim 1 wherein the one or more potent pharmaceutically active substances are budesonide and formoterol.
3. A composition according to claim 1 or 2 wherein the bulk density is from 0.30 to 0.36 g/ml.
4. A composition according to claim 1 , 2 or 3 wherein the active substance and carrier substance are substantially uniformly distributed.
5. A composition according to any one of claims 1 to 4 for use in the treatment of a respiratory disorder.
6. A process for preparing a composition according to claim 1 which comprises (a) micronising the one or more potent pharmaceutically active substances and the carrier substance;
(b) optionally conditioning the product; and
(c) spheronizing until the desired bulk density is obtained.
7. A process according to claim 6 which comprises a low energy remicronisation step after step (b).
8. Use of a composition according to any one of claims 1 to 4 in the manufacture of a medicament for use in therapy.
9. A method of treating a patient suffering from a respiratory disorder which comprises administering to the patient a therapeutically effective amount of a composition according to any one of claims 1 to 4.
AU57859/98A 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof Expired AU731192B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9700135 1997-01-20
SE9700135A SE9700135D0 (en) 1997-01-20 1997-01-20 New formulation
PCT/SE1998/000040 WO1998031352A1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof

Publications (2)

Publication Number Publication Date
AU5785998A true AU5785998A (en) 1998-08-07
AU731192B2 AU731192B2 (en) 2001-03-29

Family

ID=20405455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57859/98A Expired AU731192B2 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof

Country Status (35)

Country Link
US (2) US6030604A (en)
EP (1) EP1007017B2 (en)
JP (1) JP2010059181A (en)
KR (1) KR100528416B1 (en)
CN (1) CN1271993C (en)
AR (1) AR011080A1 (en)
AT (1) ATE288260T1 (en)
AU (1) AU731192B2 (en)
BR (1) BR9811249A (en)
CA (1) CA2277913C (en)
CZ (1) CZ296301B6 (en)
DE (1) DE69828886T3 (en)
DK (1) DK1007017T4 (en)
EE (1) EE03951B1 (en)
ES (1) ES2235311T5 (en)
HK (1) HK1025515A1 (en)
HU (1) HU228622B1 (en)
ID (1) ID21865A (en)
IL (1) IL130838A (en)
IS (1) IS2788B (en)
MY (1) MY132999A (en)
NO (1) NO327426B1 (en)
NZ (1) NZ336594A (en)
PL (1) PL192115B1 (en)
PT (1) PT1007017E (en)
RU (1) RU2194497C2 (en)
SA (1) SA98180818B1 (en)
SE (1) SE9700135D0 (en)
SI (1) SI1007017T2 (en)
SK (1) SK283950B6 (en)
TR (1) TR199901690T2 (en)
TW (1) TW557217B (en)
UA (1) UA57764C2 (en)
WO (1) WO1998031352A1 (en)
ZA (1) ZA9878B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
SE9703407D0 (en) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (en) * 1998-06-11 1998-06-11 Astra Ab New use
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
AU1786199A (en) * 1998-12-11 2000-07-03 Pharmachemie B.V. Pharmaceutical preparation for inhalation of an opioid
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
AR022695A1 (en) * 1999-01-28 2002-09-04 Schering Corp SOLID PARTICULATE CARRIER AND METHOD TO PROVIDE PARTICULATE CONTROL FOR THE DISTRIBUTION OF SIZE OF PARTICLES AND CONVERTIBLE AMORPH CONTENT DURING PREPARATION
US6623760B1 (en) * 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
TWI277425B (en) * 1999-04-13 2007-04-01 Lilly Co Eli Pulmonary administration of dry powder formulations for treating infertility
CA2273585A1 (en) 1999-05-28 2000-11-28 Canpolar East Inc. Sensors for detecting changes in temperature, ph, chemical conditions, biological conditions, radiation, electrical field and pressure
DE19962926A1 (en) * 1999-12-24 2001-06-28 Bayer Ag Comminution of a substance, especially a cardiovascular drug, comprises mixing the substance with lactose and comminuting the mixture in a jet mill
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
US20030026766A1 (en) * 2000-04-13 2003-02-06 Mark Sanders Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
FI20002177A0 (en) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj New combination for asthma therapy
FI20002215A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
FI20002216A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
CA2435982C (en) * 2001-02-06 2014-05-06 Innovata Biomed Limited Medicaments
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
AR036358A1 (en) * 2001-08-28 2004-09-01 Schering Corp A DOSE INHALER MEASURES CONTAINING A SUSPENSION FORMULATION IN AEROSOL FOR INHALATION, A PROCESS FOR THE PRODUCTION OF THE FORMULATION, THE PRODUCT AND THE USE OF A FORMULATION FOR THE MANUFACTURE OF AN ASTHMA MEDICINAL PRODUCT
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (en) 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
AU2003227710A1 (en) * 2002-05-07 2003-11-11 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
DE60323138D1 (en) * 2002-12-12 2008-10-02 Nycomed Gmbh COMBINATION MEDICAMENT OF R, R-FORMOTEROL AND CICLESONIDE
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
WO2004103379A1 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Salmeterol and ciclesonide combination
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527189C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE526850C2 (en) * 2003-06-19 2005-11-08 Microdrug Ag Pharmaceutical combined dry powder dose separated on common dose bed
SE526509C2 (en) * 2003-06-19 2005-09-27 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527200C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
WO2005020963A1 (en) 2003-09-02 2005-03-10 Ivax Corporation Process for preparing a medicament
PL1670482T5 (en) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EA011167B1 (en) * 2004-01-22 2009-02-27 Пфайзер Инк. Sulfonamide derivatives for the treatment of diseases
JO3102B1 (en) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient
AR048339A1 (en) * 2004-03-24 2006-04-19 Chiesi Farma Spa 8- HYDROXI-5 MONOCLORHYDRATE - ((1R)) -1- HYDROXI-2- (((1R) -2 (4-METOXIFENIL) -1- METHYLETYL) AMINO) ETI L) -2 (1H) - QUINOLINONE EN ACRISTALINE FORM AND THE PROCESS FOR PREPARATION
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
JP2007533387A (en) 2004-04-21 2007-11-22 イノベータ バイオメド リミテッド Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
KR20070100735A (en) * 2004-12-17 2007-10-11 씨아이피엘에이 엘티디. Pharmaceutical compounds and compositions
WO2006086270A1 (en) * 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
EP1921919B1 (en) 2005-07-14 2012-04-04 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
WO2007009164A1 (en) * 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
JP2009519972A (en) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド Method for producing a particle-based pharmaceutical for pulmonary or nasal administration
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
PL2077830T3 (en) * 2006-10-17 2013-04-30 Lithera Inc Methods, compositions, and formulations for the treatment of thyroid eye disease
WO2008100727A2 (en) 2007-02-14 2008-08-21 The Trustees Of Columbia University In The City Of New York High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Nasal administration of aqueous corticosteroid solutions
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
DE102007049931A1 (en) 2007-10-18 2009-04-23 Pharmatech Gmbh Apparatus and method for the continuous production of spherical powder agglomerates
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI632926B (en) * 2009-05-29 2018-08-21 沛爾醫療股份有限公司 Compositions, methods and systems for respiratory delivery of two or more active agents
MX2012008171A (en) * 2010-01-15 2012-12-17 Lithera Inc Lyophilized cake formulations.
US20110224229A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Novel Crystalline Form
KR20180028563A (en) 2010-10-12 2018-03-16 시플라 리미티드 Pharmaceutical composition
KR20140025312A (en) 2010-11-24 2014-03-04 리쎄라 인코오포레이티드 Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
RU2678992C2 (en) 2012-04-11 2019-02-05 Сипла Лимитед Pharmaceutical composition containing arformoterol and fluticasone furoate
RU2510267C2 (en) * 2012-06-15 2014-03-27 Шолекс Девелопмент Гмбх Inhalation preparation for treating bronchial asthma and chronic obstructive pulmonary disease and method for preparing it
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
TR201802969T4 (en) 2013-07-01 2018-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi New inhalation formulations.
CA3073195A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
MX2021014343A (en) * 2019-05-24 2022-01-06 Glenmark Pharmaceutical Ltd An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4161516A (en) † 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
SE438261B (en) * 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
ATE23272T1 (en) * 1981-07-08 1986-11-15 Draco Ab POWDER INHALER.
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB8825541D0 (en) † 1988-11-01 1988-12-07 Fisons Plc Formulation
DE69034007T2 (en) * 1989-04-28 2003-05-08 Riker Laboratories Inc., Northridge Inhalation device for dry powder
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DK0441740T3 (en) † 1990-01-29 1993-11-08 Ciba Geigy Ag Method and apparatus for dosing a granular powder
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9100341D0 (en) * 1991-02-04 1991-02-04 Astra Ab NOVEL STEROIDS
SE9100342D0 (en) * 1991-02-04 1991-02-04 Astra Ab NOVEL STEROID ESTERS
SE9302777D0 (en) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (en) * 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
DE69233150T2 (en) * 1991-06-10 2004-06-24 Schering Corp. Chlorofluorocarbon free aerosol formulations
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
US5355872B1 (en) * 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
DE69332240T2 (en) † 1992-06-12 2003-04-10 Teijin Ltd., Osaka ULTRA FINE POWDER FOR INHALATION AND PRODUCTION
AU5160893A (en) * 1992-10-16 1994-05-09 Nippon Shinyaku Co. Ltd. Method of manufacturing wax matrices
DE69415677T2 (en) * 1993-08-18 1999-06-10 Unilever N.V., Rotterdam SHAVERS
IS1736B (en) * 1993-10-01 1999-12-30 Astra Ab Methods and devices that promote increased particle aggregation
SG48049A1 (en) * 1993-10-01 1998-04-17 Astra Ab Process i
GB9404945D0 (en) † 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5647347A (en) * 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
SE9603669D0 (en) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation

Also Published As

Publication number Publication date
ES2235311T5 (en) 2011-03-31
CA2277913A1 (en) 1998-07-23
DK1007017T4 (en) 2011-02-28
PL192115B1 (en) 2006-08-31
CN1271993C (en) 2006-08-30
DE69828886D1 (en) 2005-03-10
RU2194497C2 (en) 2002-12-20
PT1007017E (en) 2005-05-31
MY132999A (en) 2007-10-31
HUP0000714A3 (en) 2000-10-30
NZ336594A (en) 2001-01-26
DE69828886T2 (en) 2006-04-06
ZA9878B (en) 1998-07-20
EP1007017B1 (en) 2005-02-02
PL334527A1 (en) 2000-02-28
HU228622B1 (en) 2013-04-29
TR199901690T2 (en) 1999-09-21
CA2277913C (en) 2007-03-06
ATE288260T1 (en) 2005-02-15
WO1998031352A1 (en) 1998-07-23
ES2235311T3 (en) 2005-07-01
CZ255799A3 (en) 1999-10-13
HUP0000714A2 (en) 2000-08-28
AU731192B2 (en) 2001-03-29
SE9700135D0 (en) 1997-01-20
AR011080A1 (en) 2000-08-02
EE03951B1 (en) 2003-02-17
ID21865A (en) 1999-08-05
EE9900295A (en) 2000-02-15
JP2010059181A (en) 2010-03-18
NO327426B1 (en) 2009-06-29
SI1007017T2 (en) 2011-03-31
NO993539L (en) 1999-09-20
SA98180818B1 (en) 2006-03-25
IS5108A (en) 1999-07-06
SK283950B6 (en) 2004-05-04
EP1007017A1 (en) 2000-06-14
TW557217B (en) 2003-10-11
ES2235311T8 (en) 2011-05-13
CZ296301B6 (en) 2006-02-15
IL130838A (en) 2005-07-25
UA57764C2 (en) 2003-07-15
BR9811249A (en) 2000-09-05
CN1243436A (en) 2000-02-02
IS2788B (en) 2012-06-15
US6287540B1 (en) 2001-09-11
IL130838A0 (en) 2001-01-28
JP2001508793A (en) 2001-07-03
JP4512204B2 (en) 2010-07-28
EP1007017B2 (en) 2010-12-08
NO993539D0 (en) 1999-07-19
SI1007017T1 (en) 2005-06-30
HK1025515A1 (en) 2000-11-17
SK95999A3 (en) 2000-01-18
KR100528416B1 (en) 2005-11-16
US6030604A (en) 2000-02-29
DE69828886T3 (en) 2011-06-01
DK1007017T3 (en) 2005-05-02
KR20000070188A (en) 2000-11-25

Similar Documents

Publication Publication Date Title
US6030604A (en) Formulation for inhalation
US6199607B1 (en) Formulation for inhalation
AU728835B2 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
EP1019033B1 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising budesonide
AU728768B2 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
JP4512204B6 (en) Novel formulation for inhalation having a bulk density of 0.28 to 0.38 G / ML, method for preparing the formulation and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)